SOPHiA Genetics posted Q2 revenue of USD 23.3 million, up 27% year over year; net loss was USD 22.4 million, flat year over year.
Gross margin fell 2.4 percentage points to 64.6% on a reported basis; adjusted gross margin slipped 2.3 points to 72.1% on a non-IFRS basis.
Adjusted EBITDA loss narrowed 27% to USD 8.8 million on a non-IFRS basis; cash and cash equivalents rose to USD 107.7 million after a USD 57.5 million offering.
Net dollar retention increased to 117% from 107% a year earlier; analyses on SOPHiA DDM climbed 22% to 115,000.
Raised 2026 revenue guidance to USD 94 million-USD 96 million from USD 92 million-USD 94 million; expects adjusted EBITDA loss of USD 29 million-USD 32 million.
SOPH•
